Vaccine-naive

ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
목요일, 5월 9, 2024
Mortality, EP, KPI, FTE, Vaccine-naive, Risk, PIN, Phase 10, FY, ADMA, Immunotherapy, Conference, Plasma, Vaccine, Total revenue, Growth, Patent, Patient, Marketing, Death, Interim, Adjustment, GAAP, Overalls, Community-acquired pneumonia, Pet industry

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its first quarter 2024 financial results and provided a business update.
  • “ADMA’s commercial success continues to unfold, and during the first quarter of 2024, we surpassed our financial expectations and delivered compounding earnings growth.
  • First Quarter 2024 Financial Results:
    Total revenues were $81.9 million for the quarter ended March 31, 2024, as compared to $56.9 million for the quarter ended March 31, 2023, an increase of $25.0 million, or approximately 44%.
  • As a result, ADMA achieved a corporate gross margin of 48% in the first quarter of 2024 as compared to 29% in the first quarter of 2023.

ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
수요일, 2월 28, 2024
PIN, Immunotherapy, Marketing, ADMA, Growth, Overalls, Patent, Death, Conference, Vaccine, Risk, Prevalence, Total revenue, GAAP, Depreciation, Patient, Vaccine-naive, FY, IVIG, Plasma, Mortality, CAP, Community-acquired pneumonia, EP

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its fourth quarter and full year 2023 financial results and provided a business update.
  • “We are pleased with our 2023 performance, which marked first-time positive adjusted net income on a full year basis.
  • We believe our unwavering focus on the immune deficient patient segment has allowed ADMA to establish itself as a premier provider of specialty biologics.
  • Fourth Quarter 2023 Financial Results:
    Total revenues were $73.9 million for the quarter ended December 31, 2023, as compared to $50.0 million for the quarter ended December 31, 2022, an increase of $23.9 million, or approximately 48%.

ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

Retrieved on: 
월요일, 1월 8, 2024
Marketing, Immunotherapy, Risk, Death, ADMA, Mortality, Patent, Community-acquired pneumonia, CAP, Adjustment, Total revenue, Vaccine-naive, Growth, Overalls, EP, FY, GAAP, Pet industry

FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively

Key Points: 
  • FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively
    RAMSEY, N.J. and BOCA RATON, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its preliminary unaudited fourth quarter and full year 2023 revenues and provided a business update.
  • Based on unaudited financial information, ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2023 will be between $72 million and $74 million and $256 million and $258 million, respectively.
  • The estimated Adjusted EBITDA amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort.
  • We estimate that an S. pneumonia hyperimmune globulin, if approved, has the potential to generate peak revenue of $300-500 Million.